Chlorambucil and rituximab are currently approved for use in patients with BIRC3 mutation in marginal zone lymphoma [4].

Chlorambucil and rituximab are currently approved for use in patients with BIRC3 mutation in mature B-cell lymphoma/leukemia [4].

BIRC3 is mutated in 2.02% of lymphoma patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in lymphoma trials with BIRC3 alterations as inclusion criteria [4].

BIRC3 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in acute lymphoblastic leukemia trials with BIRC3 alterations as inclusion criteria [4].

BIRC3 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with BIRC3 alterations as inclusion criteria [4].

BIRC3 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in chronic lymphocytic leukemia trials with BIRC3 alterations as inclusion criteria [4].

BIRC3 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in chronic myeloid leukemia trials with BIRC3 alterations as inclusion criteria [4].

BIRC3 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in multiple myeloma trials with BIRC3 alterations as inclusion criteria [4].

BIRC3 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [4].

Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in myelodysplastic syndromes trials with BIRC3 alterations as inclusion criteria [4].

BIRC3 is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in prolymphocytic leukemia trials with BIRC3 alterations as inclusion criteria [4].